ADC Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

ADC Therapeutics (NYSE:ADCT) Full Year 2024 Results

Key Financial Results

• Revenue: US$70.8m (up 1.8% from FY 2023).
• Net loss: US$157.8m (loss narrowed by 34% from FY 2023).
• US$1.63 loss per share (improved from US$2.94 loss in FY 2023).

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.

All figures shown in the chart above are for the trailing 12 month (TTM) period

ADC Therapeutics EPS Beats Expectations, Revenues Fall Short

Revenue missed analyst estimates by 2.7%. Earnings per share (EPS) exceeded analyst estimates by 4.1%.

Looking ahead, revenue is forecast to grow 34% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in the US.

Performance of the American Biotechs industry.

The company's shares are down 11% from a week ago.

Risk Analysis

You should learn about the 4 warning signs we've spotted with ADC Therapeutics (including 1 which is a bit concerning).

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.